Loading clinical trials...
Loading clinical trials...
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Conditions
Interventions
brivanib (active)
Locations
37
United States
City Of Hope National Medical Center
Duarte, California, United States
City Of Hope National Medical Center
Duarte, California, United States
Harbor UCLA Medical Center
Los Angeles, California, United States
Harbor-Ucla Medical Center
Los Angeles, California, United States
Christiana Care Health Services
Newark, Delaware, United States
University Of Miami Miller School Of Medicine
Miami, Florida, United States
Start Date
December 31, 2006
Primary Completion Date
April 30, 2010
Completion Date
April 30, 2010
Last Updated
December 1, 2023
NCT07469319
NCT07291076
NCT07365930
NCT07364357
NCT07039201
NCT07150624
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions